(-0.07%) 5 143.25 points
(-0.04%) 38 542 points
(0.01%) 17 906 points
(-0.30%) $82.38
(1.38%) $2.06
(-1.15%) $2 330.70
(-2.49%) $26.97
(-0.73%) $954.50
(0.22%) $0.934
(0.42%) $11.03
(0.25%) $0.798
(-0.24%) $93.08
1.12% ¥ 3 625.00
Live Chart Being Loaded With Signals
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality...
Stats | |
---|---|
Tagesvolumen | 47 400.00 |
Durchschnittsvolumen | 92 366.00 |
Marktkapitalisierung | 161.14B |
EPS | ¥0 ( 2024-01-30 ) |
Nächstes Ertragsdatum | ( ¥110.76 ) 2024-05-06 |
Last Dividend | ¥40.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 13.59 |
ATR14 | ¥3.42 (0.09%) |
Volumen Korrelation
Kissei Pharmaceutical Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Kissei Pharmaceutical Korrelation - Währung/Rohstoff
Kissei Pharmaceutical Finanzdaten
Annual | 2022 |
Umsatz: | ¥67.49B |
Bruttogewinn: | ¥32.38B (47.97 %) |
EPS: | ¥228.30 |
FY | 2022 |
Umsatz: | ¥67.49B |
Bruttogewinn: | ¥32.38B (47.97 %) |
EPS: | ¥228.30 |
FY | 2022 |
Umsatz: | ¥65.38B |
Bruttogewinn: | ¥31.24B (47.78 %) |
EPS: | ¥280.20 |
FY | 2021 |
Umsatz: | ¥69.04B |
Bruttogewinn: | ¥32.72B (47.39 %) |
EPS: | ¥113.25 |
Financial Reports:
No articles found.
Kissei Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥40.00 (N/A) |
¥0 (N/A) |
¥40.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.00 | 2001-03-27 |
Last Dividend | ¥40.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥794.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.68 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.36 | |
Div. Directional Score | 7.40 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8537.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7860.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7003.T | Ex Dividend Junior | 2024-03-28 | Sporadic | 0 | 0.00% | |
6356.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5210.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
4318.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3482.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2695.T | Ex Dividend Junior | 2023-10-30 | Annually | 0 | 0.00% | |
9065.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8151.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.165 | 1.500 | 6.69 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0534 | 1.200 | 8.22 | 9.86 | [0 - 0.3] |
returnOnEquityTTM | 0.0620 | 1.500 | -0.422 | -0.634 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.93 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.22 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.155 | 1.500 | 4.69 | 7.04 | [0.2 - 2] |
debtRatioTTM | 0.00608 | -1.500 | 9.90 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 141.28 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00707 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.482 | 1.000 | 5.29 | 5.29 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0345 | 1.000 | -1.310 | -1.310 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 6.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.323 | 0.800 | -1.182 | -0.946 | [0.5 - 2] |
Total Score | 10.43 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.21 | 1.000 | 8.77 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0620 | 2.50 | -0.272 | -0.634 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.29 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0896 | 1.500 | -2.74 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.114 | 1.000 | 9.65 | 0 | [0.1 - 0.5] |
Total Score | 4.36 |
Kissei Pharmaceutical
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.